Wegovy 1.7mg Dose

The 1.7mg dose usually happens around weeks 13 to 16 of your Wegovy journey. Here’s how the standard dosing schedule can increase step by step¹:

• Weeks 1-4: 0.25mg
• Weeks 5-8: 0.5mg
• Weeks 9-12: 1mg
• Weeks 13-16: 1.7mg
• Week 17 onwards: Typically, you’ll stay on 1.7mg or move up to 2.4mg, depending on how your body responds.

The 1.7mg stage is the final build-up phase before reaching your maintenance dose. At this point, your body is used to the medication, but your clinician will decide whether to stay here or move up based on your progress and side effects.

The 1.7mg dose plays an important role in helping you build tolerance. It gives your body more time to adjust to the medication’s effects before reaching the highest maintenance dose of 2.4mg. At this stage, your clinician can:

• Check how well you’re tolerating the treatment and whether side effects are easing.
• Review your appetite, energy, and weight changes to see how you’re responding.
• Decide whether to move you up to 2.4mg or keep you steady at 1.7mg if that’s working well for you.

This calculator uses data from a major clinical study on GLP-1 weight loss treatment to show what typical progress looks like. Your results will depend on your specific medication, dose, lifestyle, and medical history.

For some people, 1.7mg is the right balance – strong enough to maintain results but gentle enough to minimise side effects. You might decide to stay on 1.7mg if:

• You’re losing weight steadily and feeling well.
• You’ve found a dose that’s effective and comfortable.
• Increasing to 2.4mg causes side effects or doesn’t offer extra benefit.

If you’re stable and confident at 1.7mg, this can safely become your long-term maintenance dose.

Your clinician will assess:

• How you tolerated the previous dose of 1mg – e.g., any persistent nausea, vomiting, dehydration or gallbladder symptoms.
• Whether you have been adhering to the weekly dose on approximately the same day each week.
• Your progress in appetite reduction, weight trend, and behavioural changes (diet, exercise, etc).
• Any contraindications or emerging clinical issues (see side effects section).

You may experience:

• Continued appetite suppression. You may feel fuller, eat less, and have less cravings.
• You may notice more weight loss compared to earlier titration phases (though individual response varies).
• Gastrointestinal side effects can appear or persist at this stage. These may settle with time, dose adjustment, slower escalation or symptomatic support.
• Your health coach will monitor you regularly. At Medicspot your journey is reviewed and supported on a weekly basis, so you’re not managing this alone.

GLP-1 receptor agonists work by slowing gastric emptying and increasing fullness. Common side effects include:

• Nausea or feeling sick
• Vomiting
• Diarrhoea or constipation
• Bloating and indigestion
• Abdominal pain
• Headache or fatigue

Less common but important side effects to monitor include gallbladder disease (gallstones), acute pancreatitis, and changes in renal function or hypoglycaemia (especially if you also use diabetic medications)².

What to look out for

Mild side effects are normal and to be expected. If you feel your symptoms are more severe than you expected or you are concerned please us.

We would always want to know about stomach pains that feel a little more than a mild discomfort or if you start feeling unwell. Any unusual redness or discharge from your injection site is also something to look out for.

Here are ways to manage side effects you may experience when taking Wegovy 1.7mg:

• Take the injection on the same day each week at a consistent time.
• Follow a reduced calorie diet and increase physical activity. This supports the mechanism of Wegovy and improves weight loss outcomes.
• Stay hydrated and eat small, frequent meals if you experience nausea.
• Avoid large fatty meals or alcohol around dosing time, especially in the first several weeks at 1.7mg.
• If nausea or vomiting is persistent, your prescriber may delay the dose escalation or revert to a lower dose temporarily. This is acceptable and recommended in the official prescribing information.
• Report any severe abdominal pain, persistent vomiting, yellow skin/eyes (possible gallbladder issue), or if you have kidney problems or are undergoing surgery.

Reaching the 1.7mg stage of your Wegovy journey is an important achievement. It shows your body has adapted, your mindset is shifting, and you’re building consistency, which is the foundation for long-term success.

At this point, your clinician will work with you to decide whether to move up to 2.4mg or stay where you are. There’s no one-size-fits-all answer – the right dose is the one that’s effective, sustainable, and safe for you.

Remember that medication is only part of the story. What truly creates lasting change are the habits you’re building around food, movement, and mindset. And you don’t have to do it alone – your Medicspot health coach and clinical team are here to support you at every step.

¹ European Medicines Agency (EMA). Wegovy (semaglutide): Summary of Product Characteristics. Last accessed October 2025. [https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf]

² GOV.UK. GLP-1 receptor agonists: reminder of the potential side-effects and misuse risk. UK Drug Safety Update (2023). Last accessed October 2025. [https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuse]

³ New England Journal of Medicine. “STEP 1 Trial Summary. Once-weekly semaglutide in adults with overweight or obesity.” (2021). Last accessed October 2025. [https://www.nejm.org/doi/full/10.1056/NEJMoa2032183]

Wegovy. Wegovy dosing schedule. Last accessed October 2025. [https://www.wegovy.com/taking-wegovy/dosing-schedule.html]

Diabetes UK. Wegovy and GLP-1 medications – how they help with weight loss. Last accessed October 2025. [https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1/semaglutide/wegovy]

NHS England. Weight-management injections. Last accessed October 2025. [https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/]

Medicines.org.uk. Wegovy patient information leaflet. Last accessed October 2025. [https://www.medicines.org.uk/emc/product/13800/pil]

This article is for general information only and should not be used for the diagnosis or treatment of medical conditions. Medic Spot Limited has used all reasonable care in compiling the information but makes no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. In the event of an emergency, please call 999 for immediate assistance.

There is no guarantee of a specific weight loss medication being prescribed. Clinicians will review your online questionnaire and will recommend the most appropriate weight loss treatments for you based on your answers. In some cases the clinicians may contact you for additional information. See our Terms of Service for more information.